QVAR REDIHALER Drug Patent Profile

When do Qvar Redihaler patents expire, and when can generic versions of Qvar Redihaler launch?

Qvar Redihaler is a drug marketed by Norton Waterford and is included in one NDA. There are seventeen patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and seventy-eight patent family members in twenty-seven countries.

The generic ingredient in QVAR REDIHALER is beclomethasone dipropionate. There are twenty drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qvar Redihaler

A generic version of QVAR REDIHALER was approved as beclomethasone dipropionate by AMNEAL IRELAND LTD on December 16^th, 2025.

Summary for QVAR REDIHALER

International Patents:	278
US Patents:	17
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QVAR REDIHALER

Paragraph IV (Patent) Challenges for QVAR REDIHALER

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
QVAR REDIHALER	Inhalation Aerosol	beclomethasone dipropionate	80 mcg/actuation	207921	1	2024-07-31
QVAR REDIHALER	Inhalation Aerosol	beclomethasone dipropionate	40 mcg/actuation	207921	1	2023-10-30

US Patents and Regulatory Information for QVAR REDIHALER

QVAR REDIHALER is protected by seventeen US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017		RX	Yes	Yes	12,296,089		Y
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017		RX	Yes	Yes	11,583,643		Y
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017		RX	Yes	Yes	10,561,808		Y		Y
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-001	Aug 3, 2017		RX	Yes	Yes	11,395,889		Y		Y
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017		RX	Yes	Yes	10,086,156		Y		Y
Norton Waterford	QVAR REDIHALER	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	207921-002	Aug 3, 2017		RX	Yes	Yes	10,792,447		Y

International Patents for QVAR REDIHALER

When does loss-of-exclusivity occur for QVAR REDIHALER?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Austria

Brazil

Canada

China

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Mexico

Portugal

South Korea

Spain

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QVAR REDIHALER around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011254958
Brazil	112012029106
Canada	2799625
Canada	2887315
Canada	2936362
Canada	3019694

Last updated: July 10, 2026

AR REDIHALER (beclomethasone dipropionate HFA) investment scenario and patent fundamentals

QVAR REDIHALER is an inhaled corticosteroid (ICS) product built on beclomethasone dipropionate HFA (hydrofluoroalkane) technology. Commercial upside depends on (1) how long QVAR REDIHALER keeps exclusivity in the US, (2) the depth and enforceability of formulation and device-related IP, (3) whether generics or “authorized” substitutes can be launched on design-around, and (4) payer and channel positioning versus competing ICS inhalers. The investment-risk profile is driven primarily by US Orange Book-driven generic entry timelines and by the patent estate’s ability to block HFA-formulation and pressurized inhalation method claims.

What patents protect QVAR REDIHALER beclomethasone dipropionate HFA?

Featured answer: QVAR REDIHALER’s US patent protection is anchored in the Orange Book listing for the beclomethasone dipropionate HFA product and in any still-active patents covering pressurized metered-dose inhaler (pMDI) formulation, particle/cosuspension control, and device delivery performance. The practical investment question is whether the remaining claims are narrow (easy to design around) or broadly cover beclomethasone dipropionate in HFA with specific excipients and aerosolization parameters.

How to map the QVAR REDIHALER patent estate for diligence

For an investor, the estate should be decomposed into three layers, each with a different generic-entry risk:

1. Active ingredient plus HFA formulation patents (beclomethasone dipropionate in HFA with defined co-solvents, surfactants, particle control, and stability parameters). These drive whether a generic can file and be considered “sameness” under FDA.
2. Aerosol delivery / method patents (metering, plume characteristics, breath-actuation coordination if any, and device use protocols). These are often easier for generics to avoid by changing formulation-device interface rather than by changing the active.
3. Device and manufacturability patents (actuator, valve assembly, canister filling processes, and stability packaging). These are harder to design around if claims are written as device-structure or defined manufacturing steps.

Who typically holds the IP

The QVAR REDIHALER brand is marketed by Teva Respiratory (US), and QVAR generics and litigation history are tightly coupled to Orange Book listings for beclomethasone dipropionate HFA products. The relevant patent holders are those appearing on the US Orange Book record for QVAR REDIHALER’s specific strengths and dosage forms, including any secondary patents linked to device and formulation.

What is the Orange Book status of QVAR REDIHALER?

Featured answer: Orange Book status determines the exact expiration dates that govern potential ANDA routes and Paragraph IV litigation. For diligence, the key fields are: listed drug product patents and method-of-use patents, their expiration dates, and whether any patents are listed as “expired/withdrawn”.

Which Orange Book fields matter for investment

• Drug substance vs drug product vs method-of-use: Drug product patents often block “same route” formulation substitution; method-of-use can be narrower but can still block certain clinical claims.
• Single-patent vs family complexity: A thin estate with one blocking patent typically creates a clean generic entry window. A layered estate can cause staggered launches.
• Patent listing updates: New patents can extend risk into later years if timely listed and enforceable.

(Exact patent numbers, expiration dates, and listing counts must be read directly from the Orange Book for QVAR REDIHALER’s specific NDC/strength. Patent-to-NDC mapping is the only way to avoid “wrong product” errors.)

When does QVAR REDIHALER lose exclusivity in the US?

Featured answer: US generic entry timing is governed by the last expiring Orange Book patent tied to the specific QVAR REDIHALER NDC and by any pediatric exclusivity or regulatory exclusivity that may apply to the underlying referenced application. For pressurized metered-dose inhalers, the bottleneck is often the last formulation/device-related patent still “listed” as of the generic filing.

Exclusivity timeline mechanics investors should model

• Earliest Paragraph IV eligibility: ANDA applicants can file to challenge patents before expiration, but a launch typically depends on court outcomes or settlement terms.
• Launch gating events:
  • Patent expiration without stay
  • Court ruling against the challenger
  • Settlement permitting launch at a defined date (often with “carve-outs” or limited exclusivity)
• NDC granularity: Different strengths can have different patent coverage and different ANDA landscape.

How strong is the patent estate for QVAR REDIHALER (formulation, device, method claims)?

Featured answer: Patent strength is best assessed by claim type and breadth, not by number of patents. For QVAR REDIHALER, the most investment-relevant question is whether remaining claims cover a formulation “recipe” that a generic must reproduce, or whether claims are limited to narrow parameters that allow design-around.

Claim-breadth indicators that matter in litigation

• Defined compositional ranges for HFA co-solvents and excipients
• Defined particle or spray characteristics tied to specific assay results
• Valve/actuator structure claims that are difficult to substitute without losing performance similarity
• Process/manufacturing steps that restrict how a generic can fill, homogenize, or package the product

Invalidity and design-around risk signals

• Overlapping prior art describing beclomethasone dipropionate in HFA with similar excipient systems
• Prior disclosures of aerosol performance targets and stability parameters
• Prior art valve and canister configurations that may anticipate device claims

What generic entry risks exist for QVAR REDIHALER? (ANDA, Paragraph IV, settlement)

Featured answer: QVAR REDIHALER’s generic risk is highest when (1) the Orange Book estate is dominated by a single late-expiring patent and (2) the claims are easy to design around by changing excipient selection or aerosol performance parameters. Risk drops materially when the remaining patents cover a core delivery mechanism or require a specific formulation-device coupling.

Paragraph IV drivers to monitor

• Number of ANDA applicants tied to the specific QVAR REDIHALER NDC/strength
• Whether the Paragraph IV notice is directed at formulation patents, device patents, or method claims
• Whether the challenger uses a different inhaler technology (harder to do if claims are device-structure dependent)

Settlement economics investors track

When settlements occur, they usually establish:

• A date when the challenger can launch
• A scope limit such as NDC/strength limitation
• Sometimes a marketing or supply restriction and a “no further challenges” covenant

What patent litigation affects QVAR REDIHALER?

Featured answer: QVAR REDIHALER’s litigation impact is assessed through the status of Paragraph IV cases tied to Orange Book patents for the exact NDC/strength. Litigation affects both timeline and probability-weighted revenue duration through:

• Injunction likelihood and court-ordered stays
• Settlement terms that can delay launch beyond patent expiration
• Appellate outcomes that extend stays

What to include in a litigation model

• Filing date of the ANDA Paragraph IV notices
• Initial complaint filing date and any TRO/preliminary injunction rulings
• Claim construction outcomes
• Final invalidity/infringement determinations
• Settlement dates and permitted launch windows

(Litigation docket facts require direct case lookup by patent number and NDC-linked Orange Book entries.)

How does QVAR REDIHALER compare with other inhaled corticosteroids on safety and competitive dynamics?

Featured answer: QVAR REDIHALER competes across the ICS inhaler class against other beclomethasone devices and non-beclomethasone ICS products on formulary positioning, inhaler usability, and cost. The investment issue is whether payer preference concentrates demand in QVAR or shifts it to alternative ICS options with easier generics substitutes or better rebates.

Commercial drivers investors should quantify

• National formulary placement (preferred tiers) and managed care rebate dynamics
• Switch rates between beclomethasone HFA products and other ICS inhalers
• Patient adherence impacts from device ergonomics
• Net revenue durability in the face of generic or “drop-in” substitutions

Does QVAR REDIHALER face biosimilar or interchangeability risk?

Featured answer: No biosimilar framework applies. QVAR REDIHALER is a small-molecule ICS product; the substitution risk is from generics/authorized generics and OTC/medical device adjunct decisions, not biosimilar interchangeability.

What formulations are protected by QVAR REDIHALER patents?

Featured answer: The core protected subject matter typically includes the beclomethasone dipropionate HFA composition and its aerosolization performance inside a pMDI. The investor lens is whether claims tie protection to specific excipient combinations and stability or only broadly to the use of beclomethasone in HFA.

Formulation subtopics that determine “design-around” feasibility

• HFA fill composition and co-solvent/excipient selection
• Suspension or particle control approaches if used
• Spray plume behavior and lung deposition proxies
• Container-closure interaction and shelf-life stability

What manufacturing/IP barriers could block generic QVAR REDIHALER?

Featured answer: Barriers arise when device-structure and manufacturing process claims limit how a generic can produce a bioequivalent aerosol. If remaining patents tie to valve assembly geometry, canister filling process steps, or validated stability profiles, challengers may face both legal and technical delay.

Where manufacturing risk shows up in timelines

• Revalidation of aerosol performance after process changes
• Stability and extractables testing if device materials are redesigned
• Reduced likelihood of meeting performance similarity targets early in ANDA development

Commercial investment scenario: base case vs downside vs upside for QVAR REDIHALER

Featured answer: A credible scenario model hinges on (1) last expiration of Orange Book patents for the specific NDC/strength and (2) the probability of court outcomes or settlements delaying a generic launch.

Base case (patent expiration with limited litigation disruption)

• Revenue decays gradually ahead of final patent expiration as formulary switching and stocking behavior starts
• Generic uptake ramps after launch date, driven by payer incentives and wholesale channel readiness

Downside (early loss of enforceability or prompter generic settlement)

• Court rulings or settlements accelerate launch
• Payer formulary shifts earlier due to anticipated competitive pricing

Upside (staggered protections, harder-to-design-around claims, or settlement delays)

• Multiple patents or stronger device/formulation claims keep exclusivity longer
• Generic launches are delayed or limited to narrower strengths

Key diligence checklist for investors (QVAR REDIHALER)

• Confirm the exact Orange Book listing for QVAR REDIHALER NDC(s) and count active patents by category.
• Identify whether the last-expiring patents are formulation/product or method-of-use/device.
• Map the ANDA landscape: notice dates, patents challenged, and current court or settlement status.
• Model revenue exposure by strength (if different) and by formulary tier concentration.
• Track any changes in product supply, device performance issues, or labeling modifications that could affect switching.

---

Key Takeaways

• QVAR REDIHALER investment exposure is dominated by US Orange Book patent coverage for the specific NDC(s) and by the enforceability of HFA formulation and delivery/device claims.
• The market risk is generic/ANDA entry timing, driven by Paragraph IV outcomes and potential settlement-triggered launch dates.
• There is no biosimilar pathway; the relevant competitive threat is generic substitution in the small-molecule inhaled corticosteroid space.
• Patent “strength” should be evaluated by claim type and breadth and whether designs can shift without infringing.

---

FAQs

1. What happens to QVAR REDIHALER revenue when its last Orange Book patent expires?
2. Which QVAR REDIHALER strengths tend to face the fastest generic uptake, and why?
3. How do Paragraph IV settlements typically structure launch dates for inhaled corticosteroid pMDIs?
4. Do device-structure patents for pMDIs materially slow down generic development timelines?
5. What competitive factors drive formulary switches between QVAR REDIHALER and other ICS inhalers?

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed via FDA Orange Book database).
2. FDA. Application Review and Approval for ANDAs and Paragraph IV certifications. U.S. Food and Drug Administration. (FDA guidance and regulatory framework materials).